Dr. Kendra M. Harris
Claim this profileTulane University Health Sciences Center
Studies Breast Cancer
Studies Esophageal Cancer
11 reported clinical trials
35 drugs studied
Area of expertise
1Breast Cancer
p16 negative
EGFR positive
EGFR negative
2Esophageal Cancer
MMR negative
MMR positive
ARID1A positive
Affiliated Hospitals
Clinical Trials Kendra M. Harris is currently running
Chemotherapy + Radiation Therapy
for Head and Neck Cancer
This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to compare the usual treatment (radiation therapy with cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy, and using the usual treatment plus an immunotherapy drug, atezolizumab.
Recruiting1 award Phase 2 & 321 criteria
Hormone + Radiation Therapy
for Prostate Cancer
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving a shorter hormone therapy treatment may work the same at controlling prostate cancer compared to the usual 24 month hormone therapy treatment in patients with low gene risk score. Adding apalutamide to the usual treatment may increase the length of time without prostate cancer spreading as compared to the usual treatment in patients with high gene risk score.
Recruiting2 awards Phase 36 criteria
More about Kendra M. Harris
Clinical Trial Related7 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Kendra M. Harris has experience with
- Biospecimen Collection
- Atezolizumab
- Apalutamide
- Quality-of-Life Assessment
- Questionnaire Administration
- Data Collection
Breakdown of trials Kendra M. Harris has run
Breast Cancer
Esophageal Cancer
Prostate Cancer
Cancer
Ovarian Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Kendra M. Harris specialize in?
Is Kendra M. Harris currently recruiting for clinical trials?
Are there any treatments that Kendra M. Harris has studied deeply?
What is the best way to schedule an appointment with Kendra M. Harris?
What is the office address of Kendra M. Harris?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.